Leo Luznik

Best Publications

• Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

  Stefan O. Ciurea;Mei Jie Zhang;Andrea A. Bacigalupo;Asad Bashey

  695
  Citations

• Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide

  P.V O'Donnell;L Luznik;R.J Jones;G.B Vogelsang

  546
  Citations

• The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.

  Kenneth R. Cooke;Leo Luznik;Stefanie Sarantopoulos;Frances T. Hakim

  493
  Citations

• HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.

  Javier Bolaños-Meade;Ephraim J. Fuchs;Leo Luznik;Sophie M. Lanzkron

  457
  Citations

• Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

  Cristina Toffalori;Laura Zito;Valentina Gambacorta;Michela Riba

  404
  Citations

• Modern approaches to HLA-haploidentical blood or marrow transplantation

  Christopher G. Kanakry;Ephraim J. Fuchs;Leo Luznik

  403
  Citations

• Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation

  Leo Luznik;Paul V. O'Donnell;Paul V. O'Donnell;Ephraim J. Fuchs

  401
  Citations

• Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide

  Christopher G. Kanakry;Sudipto Ganguly;Marianna Zahurak;Javier Bolaños-Meade

  393
  Citations

• Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma

  Lauri M. Burroughs;Paul V. O'Donnell;Brenda M. Sandmaier;Barry E. Storer

  352
  Citations

• Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

  Christopher G. Kanakry;Paul V. O'Donnell;Terry Furlong;Marcos J. De Lima

  332
  Citations

• Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

  Shannon R. McCurdy;Jennifer A. Kanakry;Margaret M. Showel;Hua Ling Tsai

  328
  Citations

• Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans

  Mathangi Srinivasan;Ryan Flynn;Andrew Price;Ann Ranger

  324
  Citations

• Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

  Yvette L. Kasamon;Leo Luznik;Mary S. Leffell;Jeanne Kowalski

  314
  Citations

• The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.

  Stefan O. Ciurea;Kai Cao;Marcelo Fernadez-Vina;Piyanuch Kongtim

  269
  Citations

• Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

  Yvette L. Kasamon;Javier Bolaños-Meade;Gabrielle T. Prince;Hua Ling Tsai

  268
  Citations

• Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans

  Ryan P Flynn;Jing Du;Rachelle G. Veenstra;Dawn K Reichenbach

  245
  Citations

• NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications

  Antonio Russo;Giacomo Oliveira;Sofia Berglund;Raffaella Greco

  241
  Citations

• Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

  Sudipto Ganguly;Duncan B. Ross;Angela Panoskaltsis-Mortari;Christopher G. Kanakry

  222
  Citations

• Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

  Christopher G. Kanakry;Hua Ling Tsai;Javier Bolaños-Meade;B. Douglas Smith

  218
  Citations

• Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.

  Ryan Flynn;Katelyn Paz;Jing Du;Dawn K. Reichenbach

  208
  Citations